T. Rowe Price Investment Management, Inc. Black Diamond Therapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 10,734,389 shares of BDTX stock, worth $27.6 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
10,734,389
Previous 10,659,730
0.7%
Holding current value
$27.6 Million
Previous $49.7 Million
6.0%
% of portfolio
0.03%
Previous 0.03%
Shares
5 transactions
Others Institutions Holding BDTX
# of Institutions
117Shares Held
48.8MCall Options Held
1.84MPut Options Held
1.93M-
Bellevue Group Ag Kuesnacht, V88.52MShares$21.9 Million0.62% of portfolio
-
Vestal Point Capital, LP New York, NY5.03MShares$12.9 Million1.66% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$11.4 Million1.48% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$8.27 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.32MShares$5.96 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $93.4M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...